ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Donepezil

Also written as “Donepezil Hydrochloride”, “E2020” and “Donepezil TDS”.

Its studies are mostly in Alzheimer Disease · Down Syndrome · Lewy Body Disease · Cognitive Dysfunction · Dementia, led by 14 companies.

Drug pageDonepezil: every studyMany companies study it; this page follows only the 79 they lead. All 184 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Sep 12, 200579 company-led studies, 1 open or runningNext primary completion: May 6, 2030 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eisaiits history only391 open or runningphase 4since Sep 12, 2005Nov 9, 2004May 6, 2030phase 1 · NCT07768592
Pfizerits history only70 open or runningphase 4since Sep 9, 2005Sep 8, 2005none ahead
Coriumits history only60 open or runningphase 1since Nov 13, 2016Nov 13, 2016none ahead
Merckits history only50 open or runningphase 2since Feb 14, 2014Oct 21, 2008none ahead
Dr. Reddy's Laboratoriesits history only40 open or runningphase 1since Jan 3, 2012Jan 3, 2012none ahead
Teva Pharmaceutical Industriesits history only40 open or runningphase 1since Dec 14, 2010Dec 14, 2010none ahead
AstraZenecaits history only30 open or runningphase 1since Jul 9, 2008Jul 9, 2008none ahead
Icure Pharmaceuticalits history only30 open or runningphase 3since Jun 22, 2017May 15, 2013none ahead
GlaxoSmithKlineits history only20 open or runningphase 2since Jun 30, 2006Jun 30, 2006none ahead
Sun Pharmaceutical Industriesits history only20 open or runningphase 1since Jan 11, 2011Jan 11, 2011none ahead
Theranexus10 open or runningphase 1since Oct 2, 2018Oct 2, 2018none ahead

Also a collaborator on its studies: PT Equilab International.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Theranexus only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 2, 2018First study: phase 1 study in Cognitive DysfunctionFirst studyNCT03698695 · 152 enrolled · France

TargetBeta

ACHE →read by rule
“Acetylcholinesterase inhibitor”ChEMBL 37, by rule

Other programs on ACHE

ProgramCompanyFurthest phaseStudies
huperzine Arulewanbangde-pharmaceutical-group-co-ltdphase 47
benzgalantamine gluconaterulealpha-cognition-incphase 41
Z 338ruleZeria Pharmaceuticalphase 312

Studies

The one study Theranexus leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03698695Cognitive Dysfunction · France1CompletedOct 20, 2019152

How it is read

Names in the registry

  • “Donepezil”, 26 entries
  • “Donepezil Hydrochloride”, 14 entries
  • “E2020”, 7 entries
  • “Donepezil TDS”, 5 entries
  • “Donepezil hydrochloride”, 5 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.